» Articles » PMID: 30868890

MicroRNA-101 Regulates Autophagy, Proliferation and Apoptosis Via Targeting EZH2 in Laryngeal Squamous Cell Carcinoma

Overview
Journal Neoplasma
Specialty Oncology
Date 2019 Mar 15
PMID 30868890
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Laryngeal carcinoma is the second commonest head and neck carcinoma globally. MicroRNA-101 (miR-101) has been reported as a tumor suppressor in multiple malignancies including laryngeal squamous cell carcinoma (LSCC). However, the roles and molecular mechanisms of miR-101 in the development of LSCC have not been fully elucidated. In present study, RT-qPCR assay was performed to detect the expression of miR-101 and enhancer of zeste homolog 2 (EZH2) mRNA. Western blot assay was conducted to determine protein expression of LC3-Ⅰ, LC3-Ⅱ, p62 and EZH2. Cell proliferative capacity was evaluated by MTS assay. The effect of miR-101 alone or along with EZH2 on cell apoptosis was assessed by apoptotic index and caspase-3 activity. Bioinformatic analysis, luciferase assay and RNA immunoprecipitation (RIP) assay were carried out to investigate the interaction between miR-101 and EZH2. Results revealed that miR-101 expression was strikingly down-regulated in LSCC cell lines. Functional analyses showed that ectopic expression of miR-101 suppressed cell autophagy and proliferation and facilitated cell apoptosis in LSCC. Further investigations revealed that miR-101 inhibited EZH2 expression by direct interaction and EZH2 was highly expressed in LSCC cells. Also, EZH2 knockdown reduced the autophagic activity of LSCC cells. Moreover, restoration experiments showed that EZH2 up-regulation weakened miR-101-mediated anti-autophagy, anti-proliferation and pro-apoptosis effects in LSCC cells. In conclusion, our findings suggested that miR-101 inhibited autophagy and proliferation and promoted apoptosis via targeting EZH2 in LSCC, providing a deep insight into the pathogenesis of LSCC and hinting the pivotal roles of epigenetic modifications especially histone methylation in the development of LSCC.

Citing Articles

Treating human cancer by targeting EZH2.

Xu M, Xu C, Wang R, Tang Q, Zhou Q, Wu W Genes Dis. 2025; 12(3):101313.

PMID: 40028035 PMC: 11870178. DOI: 10.1016/j.gendis.2024.101313.


NRSN2 promotes the malignant behavior of HPV-transfected laryngeal carcinoma cells through AMPK/ULK1 pathway mediated autophagy activation.

Guo F, Wen W, Mi Z, Long C, Shi Q, Yang M Cancer Biol Ther. 2024; 25(1):2334463.

PMID: 38569536 PMC: 10993921. DOI: 10.1080/15384047.2024.2334463.


Epigenetic and post-translational modifications in autophagy: biological functions and therapeutic targets.

Shu F, Xiao H, Li Q, Ren X, Liu Z, Hu B Signal Transduct Target Ther. 2023; 8(1):32.

PMID: 36646695 PMC: 9842768. DOI: 10.1038/s41392-022-01300-8.


Contingent Synergistic Interactions between Non-Coding RNAs and DNA-Modifying Enzymes in Myelodysplastic Syndromes.

Symeonidis A, Chatzilygeroudi T, Chondrou V, Sgourou A Int J Mol Sci. 2022; 23(24).

PMID: 36555712 PMC: 9785516. DOI: 10.3390/ijms232416069.


Mesenchymal stem cell-derived exosomes as new tools for delivery of miRNAs in the treatment of cancer.

Dalmizrak A, Dalmizrak O Front Bioeng Biotechnol. 2022; 10:956563.

PMID: 36225602 PMC: 9548561. DOI: 10.3389/fbioe.2022.956563.